<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-231 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-231</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-231</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-11.html">extraction-schema-11</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <p><strong>Paper ID:</strong> paper-1fddc9998706a5072f84b8677b5de62c962d3595</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/1fddc9998706a5072f84b8677b5de62c962d3595" target="_blank">Randomized Trial of Thymectomy in Myasthenia Gravis.</a></p>
                <p><strong>Paper Venue:</strong> New England Journal of Medicine</p>
                <p><strong>Cost:</strong> 0.017</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e231.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e231.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Thymectomy (extended transsternal)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Extended transsternal thymectomy (en bloc resection of mediastinal thymic tissue)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Surgical removal of thymic tissue performed in this randomized trial; intended to remove the bulk of thymic (and ectopic) tissue to improve outcomes in acetylcholine-receptor antibody–positive generalized myasthenia gravis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Randomized Trial of Thymectomy in Myasthenia Gravis</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>thymoma_subtype_and_stage</strong></td>
                            <td>Patients with radiographic thymoma on chest CT/MRI were excluded from enrollment; one thymoma was discovered at surgery. No WHO subtype or Masaoka-Koga stage data are reported in the main text (histologic findings listed in Supplementary Appendix but not detailed here).</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_phenotype</strong></td>
                            <td>Study population: acetylcholine-receptor (AChR) antibody–positive generalized myasthenia gravis (MG). The paper notes that thymomas occur in ~10% of MG patients and thymic hyperplasia in up to ~70% of non-thymomatous MG patients; other paraneoplastic autoimmune syndromes are not described in this trial report.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmunity_frequency_and_risk_estimates</strong></td>
                            <td>Reported prevalence figures in text: 'Thymomas are present in 10% of patients with myasthenia gravis' and 'up to 70% of the remaining patients with myasthenia gravis have hyperplastic thymic changes'; no formal risk estimates (odds ratios, hazard ratios) or denominators beyond trial N are provided.</td>
                        </tr>
                        <tr>
                            <td><strong>central_tolerance_defect_evidence</strong></td>
                            <td>The authors state the thymus has a 'central role' in pathogenesis of MG but do not present molecular or histologic assays (AIRE, FEZF2, tissue-restricted antigen expression, MHC/antigen-presentation machinery) in this paper. No direct evidence for altered AIRE/Fezf2 or medullary TEC defects is provided in the main text.</td>
                        </tr>
                        <tr>
                            <td><strong>thymocyte_selection_and_T_cell_repertoire_findings</strong></td>
                            <td>Not assessed or reported in this clinical trial (no flow cytometry, TCR-seq, or thymocyte developmental assays presented).</td>
                        </tr>
                        <tr>
                            <td><strong>regulatory_T_cell_findings</strong></td>
                            <td>Not assessed or reported (no FOXP3 counts, functional Treg assays, or cytokine data presented).</td>
                        </tr>
                        <tr>
                            <td><strong>B_cell_and_autoantibody_findings</strong></td>
                            <td>Inclusion required elevated circulating AChR antibody concentrations (AChR-Ab used as an enrollment criterion). Beyond AChR-Ab, no additional autoantibodies (titin, ryanodine receptor, ANA, cytokine autoantibodies) or intratumoral germinal-center/plasma-cell data are reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>Good_syndrome_and_immunodeficiency_features</strong></td>
                            <td>Not discussed in this trial report.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_and_cytokine_signals</strong></td>
                            <td>No data on intratumoral cytokines, chemokines, checkpoint molecules, or epithelial cell signaling are presented.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_and_molecular_associations</strong></td>
                            <td>No host HLA associations, somatic tumor mutations, copy-number changes, epigenetic or AIRE-pathway molecular data are reported in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_correlates_and_temporality</strong></td>
                            <td>Design: patients with nonthymomatous, AChR-Ab–positive generalized MG of <5 years' duration randomized to thymectomy plus prednisone vs prednisone alone. Timing: surgery performed within 30 days of randomization. Clinical effect: thymectomy was associated with improved clinical status over 3 years (time-weighted QMG score 6.15 vs 8.99) and reduced prednisone requirement (average alternate-day 32 mg vs 54 mg). The paper notes thymomas can be present at diagnosis (10% prevalence) but does not present systematic longitudinal data about autoimmunity preceding vs following tumor diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_and_response_patterns</strong></td>
                            <td>Thymectomy plus prednisone vs prednisone alone (N randomized = 126). Key outcomes favoring thymectomy through 36 months: time-weighted average QMG score 6.15 vs 8.99 (estimated difference 2.85 points, 99.5% CI 0.47 to 5.22, P < 0.001); time-weighted average alternate-day prednisone 32 mg vs 54 mg (difference 22 mg; 95% CI 12 to 32; P < 0.001); fewer hospitalizations for exacerbation 9% vs 37% (P < 0.001); less azathioprine use 17% vs 48% (P < 0.001); higher minimal-manifestation status at 36 months 67% vs 47% (P = 0.03).</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>The authors reiterate that thymic abnormalities (thymoma, thymic hyperplasia) support a central role of the thymus in MG pathogenesis — implying that removal of thymic tissue reduces the source of pathogenic immune activity — but they do not provide a detailed molecular causal chain (no direct data on defective negative selection, AIRE, Treg dysfunction, or intrathymic autoantibody generation within this trial).</td>
                        </tr>
                        <tr>
                            <td><strong>key_supporting_results</strong></td>
                            <td>Clinical trial outcomes provide indirect support that removal of thymic tissue improves autoimmune disease course: QMG score difference 2.85 points favoring thymectomy (99.5% CI 0.47–5.22; P < 0.001); prednisone dose difference 22 mg (95% CI 12–32; P < 0.001); hospitalization for MG exacerbation 9% (thymectomy) vs 37% (prednisone alone), P < 0.001; azathioprine use 17% vs 48%, P < 0.001.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_and_alternative_explanations</strong></td>
                            <td>The authors note prior observational studies were inconsistent (some showing no long-term differences), and that modern immunotherapy effectiveness raised questions about surgical necessity. They acknowledge they did not test minimally invasive resections and that incomplete resection or ectopic thymic tissue may influence long-term outcomes. Histology–response correlations were planned but not yet analyzed/reported.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design_and_population</strong></td>
                            <td>Randomized, multicenter, international, rater-blinded clinical trial (MGTX). 126 patients randomized (66 thymectomy + prednisone, 60 prednisone alone). Inclusion: 18–65 years (later extended to 65), generalized nonthymomatous MG, disease duration <5 years, elevated AChR antibody. Exclusion: radiographic thymoma on CT/MRI, prior thymectomy, prior non-prednisone immunotherapy.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_strength_limitations</strong></td>
                            <td>Strengths: randomized design, multicenter, rater-blinded, standardized prednisone protocol. Limitations relevant to mechanistic inference: no molecular or cellular thymic immunology assays reported; single-blind (no sham surgery); pill-count adherence measure imprecision; histologic correlation analyses not reported in main text; trial population excluded radiographic thymoma so findings pertain to nonthymomatous MG.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Randomized Trial of Thymectomy in Myasthenia Gravis.', 'publication_date_yy_mm': '2016-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e231.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e231.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Thymoma in MG</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Thymoma-associated myasthenia gravis (thymoma in MG patients)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Presence of thymic epithelial tumor (thymoma) in a subset of MG patients; mentioned as a well-known association and considered an indication for thymectomy in thymoma cases.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Randomized Trial of Thymectomy in Myasthenia Gravis</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>thymoma_subtype_and_stage</strong></td>
                            <td>No subtype/stage details provided in this paper's main text; authors state thymoma on imaging was an exclusion criterion and one thymoma was discovered at surgery; histologic data in Supplementary Appendix only.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_phenotype</strong></td>
                            <td>Associated autoimmune/paraneoplastic phenotype discussed in context of MG (myasthenia gravis). Other thymoma-associated autoimmune syndromes not discussed in this trial report.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmunity_frequency_and_risk_estimates</strong></td>
                            <td>Text-stated frequency: 'Thymomas are present in 10% of patients with myasthenia gravis.' No case–control risk estimates or comparative statistics provided.</td>
                        </tr>
                        <tr>
                            <td><strong>central_tolerance_defect_evidence</strong></td>
                            <td>Not provided in this paper; authors cite general literature supporting thymic central role but do not present AIRE/Fezf2 or medullary TEC data for thymoma cases here.</td>
                        </tr>
                        <tr>
                            <td><strong>thymocyte_selection_and_T_cell_repertoire_findings</strong></td>
                            <td>Not assessed in this report.</td>
                        </tr>
                        <tr>
                            <td><strong>regulatory_T_cell_findings</strong></td>
                            <td>Not assessed in this report.</td>
                        </tr>
                        <tr>
                            <td><strong>B_cell_and_autoantibody_findings</strong></td>
                            <td>No thymoma-specific antibody repertoire data presented (AChR-Ab is the primary antibody measured for inclusion).</td>
                        </tr>
                        <tr>
                            <td><strong>Good_syndrome_and_immunodeficiency_features</strong></td>
                            <td>Not discussed in trial text for thymoma cases.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_and_cytokine_signals</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_and_molecular_associations</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_correlates_and_temporality</strong></td>
                            <td>Authors note thymomas are present at diagnosis in a minority (~10%) of MG patients; thymectomy is mandatory for thymoma to prevent further spread, per conventional practice (statement, no trial data).</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_and_response_patterns</strong></td>
                            <td>Thymectomy is standard of care for thymoma to prevent tumor spread; this trial excluded radiographic thymoma so does not provide systematic outcome data for thymomatous MG vs nonthymomatous MG.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>Implicit hypothesis in background: thymoma (as thymic epithelial neoplasm) disrupts normal thymic function and contributes to autoimmunity, but this paper does not detail molecular mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>key_supporting_results</strong></td>
                            <td>No new mechanistic or quantitative data on thymoma–autoimmunity mechanisms are provided in this trial report beyond the epidemiologic prevalence statement (10%).</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_and_alternative_explanations</strong></td>
                            <td>Not discussed beyond noting that surgical necessity had been questioned due to effective immunotherapy.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design_and_population</strong></td>
                            <td>This trial excluded patients with radiographic thymoma; only one thymoma was found intraoperatively among randomized patients. Therefore, the trial provides almost no data on thymoma subgroups.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_strength_limitations</strong></td>
                            <td>Very limited: trial excluded thymoma on imaging, so the paper does not address mechanistic or epidemiologic details for thymoma beyond citing prevalence figures from prior literature.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Randomized Trial of Thymectomy in Myasthenia Gravis.', 'publication_date_yy_mm': '2016-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e231.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e231.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Thymic hyperplasia in MG</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Thymic hyperplasia (non-thymomatous) in myasthenia gravis patients</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Enlargement/hyperplasia of thymic tissue commonly reported in nonthymomatous MG; cited here as frequent (up to ~70%) and supportive of a central thymic role in disease.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Randomized Trial of Thymectomy in Myasthenia Gravis</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>thymoma_subtype_and_stage</strong></td>
                            <td>Not applicable (hyperplasia rather than neoplasm); no histologic subtype details reported in main text.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_phenotype</strong></td>
                            <td>Associated with acetylcholine-receptor antibody–positive MG; no other autoimmune phenotypes detailed here.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmunity_frequency_and_risk_estimates</strong></td>
                            <td>Text cites 'up to 70% of the remaining patients with myasthenia gravis have hyperplastic thymic changes' (no denominator or confidence intervals provided).</td>
                        </tr>
                        <tr>
                            <td><strong>central_tolerance_defect_evidence</strong></td>
                            <td>Not studied in this trial; authors reference the high frequency of hyperplasia as evidence for thymic involvement but present no direct molecular assays (AIRE/Fezf2/TSA expression) in this report.</td>
                        </tr>
                        <tr>
                            <td><strong>thymocyte_selection_and_T_cell_repertoire_findings</strong></td>
                            <td>Not assessed in the trial.</td>
                        </tr>
                        <tr>
                            <td><strong>regulatory_T_cell_findings</strong></td>
                            <td>Not assessed.</td>
                        </tr>
                        <tr>
                            <td><strong>B_cell_and_autoantibody_findings</strong></td>
                            <td>No specific intrathymic B-cell/germinal-center or autoantibody generation data presented in this trial.</td>
                        </tr>
                        <tr>
                            <td><strong>Good_syndrome_and_immunodeficiency_features</strong></td>
                            <td>Not discussed in relation to hyperplasia here.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_and_cytokine_signals</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_and_molecular_associations</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_correlates_and_temporality</strong></td>
                            <td>Authors present hyperplasia frequency as a background observation supporting thymus involvement in MG pathogenesis; the trial itself enrolled nonthymomatous patients, many of whom may have hyperplasia, but histology–response analyses are not reported in the main text.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_and_response_patterns</strong></td>
                            <td>Thymectomy (extended transsternal) intended to remove hyperplastic thymic tissue; trial-level clinical improvements after thymectomy are reported (see thymectomy entity) but no subgroup analysis correlating hyperplasia presence with outcome is provided here (authors state planned histologic correlation not yet conducted).</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>Implicit: thymic hyperplasia may reflect or drive abnormal intrathymic immune processes that promote autoreactive T-cell selection and AChR autoimmunity, but the authors do not provide mechanistic data in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>key_supporting_results</strong></td>
                            <td>Epidemiologic background statement: up to ~70% of nonthymomatous MG patients have thymic hyperplasia; no trial-derived quantitative correlation provided yet.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_and_alternative_explanations</strong></td>
                            <td>Authors note inconsistent observational data in past studies regarding long-term benefit of thymectomy, suggesting that hyperplasia alone may not fully determine treatment response.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design_and_population</strong></td>
                            <td>Referenced as background literature; the randomized trial enrolled nonthymomatous MG patients (imaging-negative for thymoma) but did not report systematic thymic hyperplasia assessment results in the main text.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_strength_limitations</strong></td>
                            <td>No direct histologic/molecular hyperplasia data reported in main text; histology–response analyses are pending per authors.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Randomized Trial of Thymectomy in Myasthenia Gravis.', 'publication_date_yy_mm': '2016-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e231.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e231.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Ectopic thymic tissue / incomplete resection</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Ectopic thymic tissue and effects of incomplete thymic resection</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Literature-cited concept that residual/ectopic thymic tissue left after less-extensive or minimally invasive resections can negatively affect long-term clinical outcomes in MG.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Randomized Trial of Thymectomy in Myasthenia Gravis</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>thymoma_subtype_and_stage</strong></td>
                            <td>Not applicable; relates to distribution of thymic tissue rather than tumor subtypes.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_phenotype</strong></td>
                            <td>Impacts clinical course of myasthenia gravis according to cited literature (worse outcomes at >7-year follow-up in presence of ectopic thymus or incomplete resection).</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmunity_frequency_and_risk_estimates</strong></td>
                            <td>No numeric risk estimates provided in the trial text; authors cite studies reporting negative effects of ectopic thymus on outcomes at follow-up beyond 7 years (reference 30) and reports linking incomplete resections with lack of improvement (references 31–33).</td>
                        </tr>
                        <tr>
                            <td><strong>central_tolerance_defect_evidence</strong></td>
                            <td>Not directly addressed with molecular data in this paper; mechanistic implication is that residual thymic tissue may continue to support aberrant thymic selection/export of autoreactive cells.</td>
                        </tr>
                        <tr>
                            <td><strong>thymocyte_selection_and_T_cell_repertoire_findings</strong></td>
                            <td>Not assessed here; implication is that residual tissue may permit ongoing export of pathogenic T cells, but no T-cell repertoire data presented.</td>
                        </tr>
                        <tr>
                            <td><strong>regulatory_T_cell_findings</strong></td>
                            <td>Not assessed.</td>
                        </tr>
                        <tr>
                            <td><strong>B_cell_and_autoantibody_findings</strong></td>
                            <td>Not assessed with tumor- or ectopic tissue-specific data in this trial.</td>
                        </tr>
                        <tr>
                            <td><strong>Good_syndrome_and_immunodeficiency_features</strong></td>
                            <td>Not discussed in relation to ectopic tissue.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_and_cytokine_signals</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_and_molecular_associations</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_correlates_and_temporality</strong></td>
                            <td>Authors discuss that minimally invasive techniques may leave ectopic thymic tissue in perithymic or pericardial fields and that ectopic thymus has been associated with worse outcomes in some longer-term series; incomplete resections have been associated with lack of clinical improvement in reported cases.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_and_response_patterns</strong></td>
                            <td>Authors emphasize extended transsternal thymectomy aims to remove 85–95% of thymic tissue; they did not test minimally invasive approaches in this trial. They cite literature suggesting incomplete resection/ectopic tissue may reduce long-term benefit.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>Practical mechanistic implication: residual thymic/ectopic tissue may continue to generate or maintain autoreactive lymphocytes that drive MG, undermining full clinical remission when not fully resected.</td>
                        </tr>
                        <tr>
                            <td><strong>key_supporting_results</strong></td>
                            <td>No trial-derived quantitative data in this report; the assertion rests on prior studies cited (refs 30–33) rather than on data generated in MGTX.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_and_alternative_explanations</strong></td>
                            <td>The trial did not compare surgical techniques; authors note minimally invasive approaches can have similar early outcomes per other reports, but long-term effects regarding ectopic tissue remain a concern.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design_and_population</strong></td>
                            <td>Concept is based on cited observational/cohort surgical series (references in Discussion). MGTX used extended transsternal technique to maximize resection and did not test or randomize less-extensive approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_strength_limitations</strong></td>
                            <td>Discussion-level citations only; no randomized comparison of surgical completeness or long-term ectopic-thymus assessments in this trial. The effect on mechanistic inference is indirect.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Randomized Trial of Thymectomy in Myasthenia Gravis.', 'publication_date_yy_mm': '2016-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Immunopathogenesis of myasthenia gravis <em>(Rating: 2)</em></li>
                <li>Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms <em>(Rating: 2)</em></li>
                <li>Thymectomy for myasthenia gravis: analysis of the controversies regarding technique and results <em>(Rating: 1)</em></li>
                <li>Myasthenia gravis <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>